Genentech's Phase II Mmotion150 study for Tecentriq compared Tecentriq plus Avastin and Tecentriq monotherapy to sunitinib alone reinforced the potential of the combination drug for the treatment of patients with previously untreated, locally advanced or metastatic renal cell carcinoma (mRCC).
The company presented the results at the 2017 Genitourinary Cancers Symposium in Orlando, Florida. The study, which was the first randomized clinical trial to evaluate the combination of Tecentriq and Avastin, was set up to inform further clinical development.
“These Phase II results support the scientific rationale for potentially combining Tecentriq and Avastin in people with this type of kidney cancer,” Dr. Sandra Horning, chief medical officer and head of Global Product Development, said. “There is a significant need for new treatment options for people living with advanced RCC, a disease where currently only about one in 10 people are alive beyond five years following diagnosis.”
Genentech noted in its press release that it is also evaluating the combination of Tecentriq and Avastin compared to sunitinib in a Phase III study.
Alerts Sign-up